株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インドの非侵襲的出生前遺伝学的検査 (NIPT) 市場の見通し

Indian NIPT Market Outlook 2022

発行 RNCOS E-Services Pvt. Ltd. 商品コード 371093
出版日 ページ情報 英文 110 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
インドの非侵襲的出生前遺伝学的検査 (NIPT) 市場の見通し Indian NIPT Market Outlook 2022
出版日: 2016年09月01日 ページ情報: 英文 110 Pages
概要

インドの非侵襲的出生前遺伝学的検査 (NIPT) 市場は、絶好の成長機会が見込まれています。

当レポートでは、インドのNIPT市場について調査分析し、潜在的市場、マクロ経済要因、医療インフラ、人口統計、利用可能なNIPT検査、規制シナリオなど、体系的な情報を提供しています。

第1章 アナリストの見解

第2章 調査手法

第3章 NIPTの紹介

  • インドで利用可能な検査
  • その他の検査

第4章 胎児に対するダウン症 (DS) のリスクと母親の年齢との関連

第5章 インド:マクロ経済の要因、医療インフラ、人口統計

  • 国別プロファイル
  • 医療費
  • 病院、サブセンター、PHC、CHC
  • 病理検査室
  • 体外受精 (IVF) クリニック
  • 人口

第6章 インドのNIPT:潜在的市場

  • 潜在的な顧客基盤
  • 外国企業向け市場参入戦略
  • 産婦人科医によるインドのNIPTの見通し

第7章 規制シナリオ

第8章 世界のNIPT企業

  • Ariosa Diagnostics
  • Sequenom
  • Verinata
  • Natera
  • BGI
  • Berry Genomics

第9章 インドのNIPT企業

  • MedGenome Labs Pvt. Ltd.
  • Igenomix India

第10章 インドの病理サービス市場の主要企業

  • SRL Diagnostics
  • Dr. Lal Pathlabs
  • Metropolis India
  • Thyrocare
  • Quest Diagnostics

第11章 インドの体外受精 (IVF) 主要クリニック

  • Bourn Hall Clinic
  • Southend Fertility and IVF Centre
  • Morpheus IVF Fertility Center
  • Bloom Fertility Center
  • Manipal Ankur
  • Cloudnine Fertility
  • Nova IVI Fertility
  • Srushti Test Tube Baby Center
目次

NIPT helps obstetricians and pregnant women over different age-groups to better manage their pregnancy at a very early stage. Over the last few years, an increasing number of women in Tier-1 cities in India are giving preference to their career, and are opting for childbearing at a later age, stretching to their 30s. As a result, a rising trend of conception related complications can be observed in Indian cities. In India, around 80,000-100,000 IVF cycles are performed annually. Also, due to the large number of births, India has the largest number of babies born with chromosomal disorders in the world. Every year, between 23,000 and 29,000 children are born with Down's syndrome in India, the highest in the world. Up to 90% of such cases can be detected if pregnant mothers opt for genetic screening, which represents a tremendous opportunity for NIPT tests in India in future.

According to RNCOS' new research report "Indian NIPT Market Outlook 2022", with the launch of NIPT tests, India represents a great opportunity for the growth of NIPT. In this regard, in October 2015, MedGenome collaborated with Natera for providing Panorama test in India. The company performed 1000 free NIPT test to identify the pattern of chromosomal abnormalities in fetus. However, factors such as lack of awareness relatively lower affordability, and a high number of births taking place in rural India limit the growth of the industry.

The report provides the potential market for NIPT in India. Furthermore, the report also provides a depiction of macro-economic factors, healthcare infrastructure and population demographics to assess the industry potential and growth. The report also covers a brief description regarding the available NIPT tests in India as well as in global market. Moreover, regulatory scenario has been prudently analyzed to reflect a clear picture of the immense possibilities in the Indian NIPT market.

Pathology labs and IVF clinics in India are rapidly expanding their networks, and witnessing a huge surge in fertility tourism and so in NIPT. The report also includes the findings from another RNCOS survey namely "Gynecologists survey to assess the potential for NIPT in India", which reveal moderate awareness level of NIPT in India and highlights tremendous scope of NIPT that could revolutionize the prenatal diagnosis scenario in India.

The last section of the report discusses about the prominent players in the global as well as Indian market with a brief business overview and analysis of their strengths and weaknesses, which will act as a pristine source of business intelligence for players looking to enter the highly lucrative Indian NIPT market. Besides, detailed profiling of Indian pathology labs and IVF clinics will help the medical centers who are seeking for partnerships and collaborations to make an informed decision. Overall, the research contains exhaustive information that will help clients in formulating market strategies, and assessing opportunity and potential areas in the Indian NIPT market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Introduction to Non-Invasive Prenatal Testing (NIPT)

  • 3.1 Tests Available in India
    • 3.1.1 Panorama
    • 3.1.2 NACE
  • 3.2 Other Tests
    • 3.2.1 MaterniT21 PLUS
    • 3.2.2 Verifi
    • 3.2.3 Harmony
    • 3.2.4 NIFTY
    • 3.2.5 Bambni

4. Association of Down's syndrome Risk to Fetus with Mother's Age

5. India: Macro-Economic Factors, Healthcare Infrastructure and Population Demographics

  • 5.1 Country Profile
  • 5.2 Healthcare Spending
  • 5.3 Hospitals, Sub-Centres, PHCs, CHCs
  • 5.4 Pathology Labs
  • 5.5 In-Vitro Fertilization Clinics
  • 5.6 Population

6. NIPT India: Market Potential

  • 6.1 Potential Customer Base
  • 6.2 Market Entry Strategy for Foreign Players
    • 6.2.1 Whether one should Setup a Lab in India or Send Samples to Base Country?
    • 6.2.2 Who should be Company's Face to Customer?
    • 6.2.3 How should the Consumer be Allured?
  • 6.3 Gynecologists and Obstetricians Outlook on NIPT in India: Survey Findings
    • 6.3.1 Respondent Demographics
    • 6.3.2 Current Challenges of Prenatal Testing: Indian Scenario
    • 6.3.3 Awareness Level for NIPT
    • 6.3.4 Gynecologists and Obstetricians Opinion

7. Regulatory Scenario

8. Global NIPT Players

  • 8.1 Ariosa Diagnostics
    • 8.1.1 Business Overview
    • 8.1.2 Strengths and Weaknesses
  • 8.2 Sequenom
    • 8.2.1 Business Overview
    • 8.2.2 Strengths and Weaknesses
  • 8.3 Verinata
    • 8.3.1 Business Overview
    • 8.3.2 Strengths and Weaknesses
  • 8.4 Natera
    • 8.4.1 Business Overview
    • 8.4.2 Strengths and Weaknesses
  • 8.5 BGI
    • 8.5.1 Business Overview
    • 8.5.2 Strengths and Weaknesses
  • 8.6 Berry Genomics
    • 8.6.1 Business Overview
    • 8.6.2 Strengths and Weaknesses

9. Indian NIPT Players

  • 9.1 MedGenome Labs Pvt. Ltd.
    • 9.1.1 Business Overview
    • 9.1.2 Strengths and Weaknesses
  • 9.2 Igenomix India
    • 9.2.1 Business Overview
    • 9.2.2 Strengths and Weaknesses

10. Key Players in Indian Pathological Services Market

  • 10.1 SRL Diagnostics
    • 10.1.1 Business Overview
    • 10.1.2 Strengths and Weaknesses
  • 10.2 Dr. Lal Pathlabs
    • 10.2.1 Business Overview
    • 10.2.2 Strengths and Weaknesses
  • 10.3 Metropolis India
    • 10.3.1 Business Overview
    • 10.3.2 Strengths and Weaknesses
  • 10.4 Thyrocare
    • 10.4.1 Business Overview
    • 10.4.2 Strengths and Weaknesses
  • 10.5 Quest Diagnostics
    • 10.5.1 Business Overview
    • 10.5.2 Strengths and Weaknesses

11. Key IVF Clinics in India

  • 11.1 Bourn Hall Clinic
    • 11.1.1 Business Overview
    • 11.1.2 Strengths and Weaknesses
  • 11.2 Southend Fertility and IVF Centre
    • 11.2.1 Business Overview
    • 11.2.2 Strengths and Weaknesses
  • 11.3 Morpheus IVF Fertility Center
    • 11.3.1 Business Overview
    • 11.3.2 Strengths and Weaknesses
  • 11.4 Bloom Fertility Center
    • 11.4.1 Business Overview
    • 11.4.2 Strengths and Weaknesses
  • 11.5 Manipal Ankur
    • 11.5.1 Business Overview
    • 11.5.2 Strengths and Weaknesses
  • 11.6 Cloudnine Fertility
    • 11.6.1 Business Overview
    • 11.6.2 Strengths and Weaknesses
  • 11.7 Nova IVI Fertility
    • 11.7.1 Business Overview
    • 11.7.2 Strengths and Weaknesses
  • 11.8 Srushti Test Tube Baby Center
    • 11.8.1 Business Overview
    • 11.8.2 Strengths and Weaknesses

List of Figures:

  • Figure 3-1: Panorma Test Validation Results
  • Figure 3-2: Coverage of the NACE Test
  • Figure 3-3: MaterniT21 PLUS Test Validation Results
  • Figure 3-4: Verifi Test Validation Results
  • Figure 3-5: Harmony Test Validation Results
  • Figure 3-6: NIFTY Test - Summary of Phase I Clinical Trial
  • Figure 3-7: NIFTY Test - Summary of Phase II Clinical Trial
  • Figure 5-1: Healthcare Spending Per Head (US$), 2015-2022
  • Figure 5-2: Consumer Healthcare Spending (Billion US$), 2015-2022
  • Figure 5-3: Share of Diagnostic Services in Total Healthcare Expenditure (%), 2015
  • Figure 5-4: Breakup of Public Hospitals by Urban and Rural India (%), 2013
  • Figure 5-5: Breakup of Public Hospitals Beds by Urban and Rural India (%), 2013
  • Figure 5-6: Forecast for Share of Organized Pathology Services Market (2022)
  • Figure 5-7: IVF Clinics Presence by Number of Cycles Performed (%), 2015
  • Figure 5-8: IVF Clinics Presence by Number of Cycles Performed and Structure (%), 2015
  • Figure 5-9: Population (Million), 2015-2022
  • Figure 5-10: Middle Class Household (Million), 2015-2022
  • Figure 6-1: India - Number of Births (Million), 2015-2022
  • Figure 6-2: India - Number of Births by Mother's Risk of Down's Syndrome (%), 2015
  • Figure 6-3: Number of Households Earning more than US$ 10,000 Per Annum ('000) 2015-2022
  • Figure 6-4: Factors Influencing the Indian NIPT Consumer
  • Figure 6-5: Respondent Gynecologists by Tier
  • Figure 6-6: Respondent Gynecologists by Region
  • Figure 6-7: Recommendations for Amniocentesis/CVS per Year
  • Figure 6-8: Challenges with Invasive Prenatal Tests
  • Figure 6-9: Are you Aware of DNA sequencing Based Non-Invasive Prenatal Tests (NIPT)?
  • Figure 6-10: Are you Aware of Technology used in NIPT?
  • Figure 6-11: What NIPT Players are you Aware of?
  • Figure 6-12: Respondents who are Interested in NIPT Post Being Made Aware about its Advantages
  • Figure 6-13: Age-Based Profile of Patient to Whom Respondents will Recommend NIPT
  • Figure 6-14: Respondents Who Recommend Integration of NIPT with Regular Maternal Screens

List of Tables:

  • Table 3-1: Comparison of Features of Key NIPT Tests in APAC NIPT Market
  • Table 3-2: Bambni Test - Summary of Phase I Clinical Trial
  • Table 3-3: Bambni Test - Summary of Phase II Clinical Trial
  • Table 4-1: Risk of Down's Syndrome with Rise in Maternal Age
  • Table 5-1: Key Economic Indicators (2015)
  • Table 5-2: State-wise Breakup of Sub Centres, PHCs and CHCs (2015)
  • Table 5-3: Population Break-up by Age-Group (Million), 2015-2022
  • Table 6-1: India - Number of Births by Age of Mother and Region of Birth (2015)
  • Table 6-2: India - NIPT Potential Market (Million US$) and Potential Customers (2016)
  • Table 11-1: Presence of Bourn Hall Clinic
  • Table 11-2: Presence of Southend Fertility and IVF Center
  • Table 11-3: Presence of Morpheus IVF Fertility Center
  • Table 11-4: Presence of Bloom Fertility Center
  • Table 11-5: Presence of Manipal Ankur
  • Table 11-6: Presence of Cloudnine Fertility
  • Table 11-7: Presence of Nova IVI Fertility
  • Table 11-8: Presence of Srushti Test Tube Centre
Back to Top